Please Wait
Applying Filters...
menu
    • menu
    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-06-09

    Virtual Booth

    An Enquiry

    Menu

    Encoberminogene Rezmadenovec

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 554Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Exelixis Reports Positive STELLAR-002 Trial Results at ASCO 2025
    Exelixis Reports Positive STELLAR-002 Trial Results at ASCO 2025

    22 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250522412302/en/Exelixis-Announces-Encouraging-Results-from-Phase-1b2-STELLAR-002-Trial-Evaluating-Zanzalintinib-in-Combination-with-Immune-Checkpoint-Inhibitors-in-Advanced-Kidney-Cancer-at-ASCO-2025

    BUSINESSWIRE
    22 May 2025
    Share Share
    Exelixis Announces Q3 2024 Financial Results and Update
    Exelixis Announces Q3 2024 Financial Results and Update

    29 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241029473805/en

    BUSINESSWIRE
    29 Oct 2024
    Share Share
    Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial
    Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial

    04 Dec 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231201184887/en

    BUSINESSWIRE
    04 Dec 2023
    Share Share
    Exelixis and Arcus Announce Trial Collaboration to Evaluate Zanzalintinib
    Exelixis and Arcus Announce Trial Collaboration to Evaluate Zanzalintinib

    04 Dec 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231203437225/en

    BUSINESSWIRE
    04 Dec 2023
    Share Share
    Exelixis Announces Results from Expansion Cohort of Phase 1b STELLAR-001 Trial
    Exelixis Announces Results from Expansion Cohort of Phase 1b STELLAR-001 Trial

    10 Nov 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231106261142/en

    BUSINESSWIRE
    10 Nov 2023
    Share Share